Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Stanulla

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.
Blood|February 14, 2014
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesisJulia Skokowa, Doris Steinemann, Jenny E Katsman-Kuipers, et al.
Scientific Reports|October 15, 2015
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2AJayaram Vijayakrishnan, Marc Henrion, Anthony V Moorman, et al.
Blood Advances|October 25, 2019
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, et al.
Nature Communications|November 27, 2019
Identification of four novel associations for B-cell acute lymphoblastic leukaemia riskJayaram Vijayakrishnan, Maoxiang Qian, James B Studd, et al.
Blood|June 1, 2012
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemiaPhilipp A Greif, Annika Dufour, Nikola P Konstandin, et al.
Blood|September 3, 2013
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotypeGabriele Migliorini, Bettina Fiege, Fay J Hosking, et al.
Haematologica|May 28, 2016
Characterization of leukemias with ETV6-ABL1 fusionMarketa Zaliova, Anthony V Moorman, Giovanni Cazzaniga, et al.
Journal for Immunotherapy of Cancer|October 10, 2025
Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumorsPeter J Madsen, Anna Melissa Schlitter, Carina Flemmig, et al.
Haematologica|October 12, 2019
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocolsGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.
Blood|February 14, 2014
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesisJulia Skokowa, Doris Steinemann, Jenny E Katsman-Kuipers, et al.
Scientific Reports|October 15, 2015
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2AJayaram Vijayakrishnan, Marc Henrion, Anthony V Moorman, et al.
Blood Advances|October 25, 2019
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, et al.
Nature Communications|November 27, 2019
Identification of four novel associations for B-cell acute lymphoblastic leukaemia riskJayaram Vijayakrishnan, Maoxiang Qian, James B Studd, et al.
Blood|June 1, 2012
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemiaPhilipp A Greif, Annika Dufour, Nikola P Konstandin, et al.
Blood|September 3, 2013
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotypeGabriele Migliorini, Bettina Fiege, Fay J Hosking, et al.
Haematologica|May 28, 2016
Characterization of leukemias with ETV6-ABL1 fusionMarketa Zaliova, Anthony V Moorman, Giovanni Cazzaniga, et al.
Journal for Immunotherapy of Cancer|October 10, 2025
Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumorsPeter J Madsen, Anna Melissa Schlitter, Carina Flemmig, et al.
Haematologica|October 12, 2019
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocolsGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Pageof 15